EPCAM and cancer: FR@Z-pTA NPs not only capture more than 88% of rare cancer cells for both EpCAM-positive cells (MCF-7, HepG2) and EpCAM-negative cells (MDA-MB-231, HeLa) but also effectively release the captured cells with high efficiency (>80%) and viabilities (>90%) under cell-friendly pH/ATP stimuli.